Navigation Links
Many Alzheimer's patients get drugs with opposing effects
Date:10/25/2011

SEATTLE, WAYou wouldn't brake your car while stepping on the gasor wash down a sleeping pill with espresso. Yet many people taking common Alzheimer's disease medicationscholinesterase inhibitorsare given medications with anticholinergic properties, which oppose their effects. Group Health Research Institute scientists investigated how often that happens and reported on the consequences in an "Early View" study e-published in the Journal of the American Geriatrics Society.

"Cholinesterase inhibitors are today's primary therapy for slowing Alzheimer's disease," said study leader Denise Boudreau, PhD, RPh, an associate scientific investigator at Group Health Research Institute. "Anticholinergic properties are often found in drugs commonly used to treat gastrointestinal disorders, allergies, urinary incontinence, depression, and Parkinson's disease, and they can have negative effects on cognition and function in the elderly. There's concern that if someone is taking both types of drugscholinesterase inhibitors and anticholinergic medicationsthey will antagonize each other, and neither will work."

In clinical trials, cholinesterase inhibitors show modest effects against the functional and cognitive decline of people with Alzheimer's disease. These medications, such as donepezil (Aricept) work by inhibiting the breakdown of acetylcholine, which sends signals in the nervous system. By contrast, anticholinergicssuch as diphenhydramine (Benadryl) and oxybutynin (Ditopan)block the action of acetylcholine. Since the two types of drugs have opposite effects, it makes sense not to give both kinds of drugs to an individual person. But until Dr. Boudreau's study, few researchers had explored how often patients are prescribed both types of medications and which harms this might cause.

Dr. Boudreau and colleagues conducted a retrospective cohort study of 5,625 people aged 50 or older who received a new prescription for cholinesterase inhibitors between 2000 and 2007. The researchers used electronic pharmacy records of Group Health Cooperative and Kaiser Permanente Colorado, nonprofit health care systems that together provide care to more than a million people. The research team found patients who also had a prescription for anticholinergics from the year before their cholinesterase prescription until the analysis ended on December 31, 2008, or the patient left the health care system or died. The study was the first to use state death records and insurance claims for nursing home care to look for effects of taking both drug types.

The researchers found:

  • Of the cholinesterase inhibitor users, 37 percent were also taking at least one anticholinergic drug, and more than 11 percent took two or more. This was similar to other studies of Medicare beneficiaries.

  • For those using both medication types, dual use generally lasted three to four months, but 25 percent used both classes of drugs for more than a year.

  • Anticholinergics were already being used in 23 percent of people receiving a new cholinesterase inhibitor prescription, and 77 percent continued, even after starting the cholinesterase inhibitor.

  • Subjects using both medication types were not more likely to enter a nursing home or to die than those taking only cholinesterase inhibitors.

"It's reassuring that we did not observe an association between simultaneous use of the two types of drugs and increased risk of death or nursing home placement," said Dr. Boudreau. "But concomitant use of these drugs is, at the very least, not optimal clinical practice." Preventing concurrent use of opposing drugs could also be a chance to reduce waste in health care spending, since a month of donepezil treatment costs approximately $180.

One reason that health care providers might prescribe conflicting medications is that dementia patients often have multiple medical conditions. Also, anticholinergics are often given to counteract the side effects of cholinesterase inhibitors, which are one of the few available treatments for people with Alzheimer's. Dr. Boudreau hopes the study raises awareness about the potential inappropriateness of prescribing both types of drugsand stimulate discussions about the best way to make therapeutic decisions for people with Alzheimer's.

"Providers, families, and patients should carefully consider the extent to which demonstrated benefits or harms in an individual patient justify long-term use of these drugs," said Dr. Boudreau. "A good first step is to have clearly agreed-upon goals for therapy and a plan to monitor for effects and side effects." Now Group Health Research Institute scientists have started to work with Group Health Cooperative on steps like these to improve the quality of care.


'/>"/>

Contact: Rebecca Hughes
hughes.r@ghc.org
206-287-2055
Group Health Research Institute
Source:Eurekalert  

Related medicine news :

1. Mood, cognition and sleep patterns improve in Alzheimers patients after cataract surgery
2. Vitamin B-based treatment for corneal disease may offer some patients a permanent solution
3. Rehab helps heart patients live longer -- but they have to show up
4. Biomarker detects graft-versus-host-disease in cancer patients after bone marrow transplant
5. PATH B, a comprehensive support program in Europe for patients with chronic hepatitis B launched
6. NIPPV linked to increased hospital mortality rates in small group of patients
7. Hospital patients suffer in shift shuffle
8. ASE-EAE to issue guidelines for the echocardiographic evaluation of cancer patients
9. Start HIV Drug Treatment Early in Patients With TB: Studies
10. Early HIV treatment dramatically increases survival in patients co-infected with tuberculosis
11. Most breast cancer patients do not have breast reconstruction surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Many Alzheimer's patients get drugs with opposing effects
(Date:5/31/2016)... ... , ... Spectrum Aquatics has launched a brand new ADA pool lift, the ... the user in mind. , “Over the last two years our key customers and ... lbs lift is a necessary requirement for certain facilities with specific needs,” said Nabil ...
(Date:5/31/2016)... ... May 31, 2016 , ... Interest is on the ... tool and as an orthogonal tool for RNAi hit validation. A key reason may ... guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. , ...
(Date:5/31/2016)... ... 2016 , ... TeaZa® Energy, LLC announces the launch of a ... Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be available to customers exclusively ... The new flavor is best described as a juicy, taste bud takeover. A ...
(Date:5/31/2016)... ... May 31, 2016 , ... MinerEye ... Vendors in Security Infrastructure Protection report by Gartner1 Inc. , Each year, Gartner ... research reports evaluating these innovative vendors and their products and services. , According ...
(Date:5/31/2016)... ... 31, 2016 , ... Advertising Age has recognized SourceLink, ... for the tenth consecutive year as a Top 20 Marketing Services Agency. Final ... ranked eighteenth in the “U.S. CRM/Direct Marketing Agency” category. , Recent investments ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... May 31, 2016 ... Assembly zur Eliminierung von viraler Hepatitis    ... historische Verpflichtung eingegangen, virale Hepatitis bis 2030 zu ... World Health Assembly haben sich die Staaten einstimmig ... Hepatitis (Global Viral Hepatitis Strategy) zu verabschieden, was ...
(Date:5/30/2016)... 2016 Transparency Market Research has ... Systems Market - Global Industry Analysis, Size, Share, Growth, ... report, the global advanced (3D/4D) visualization systems market was ... anticipated to expand at a CAGR of 6.4% from ... 2024. Advanced (3D/4D) visualization systems have propelled ...
(Date:5/30/2016)... , May 30, 2016 ... "Healthcare Analytical Testing Services Market by Type (Stability, ... Services), by End User (Pharmaceutical Companies, Medical Device ... MarketsandMarkets, The market witnessed healthy growth during the ... a CAGR of 11.3% between 2016 and 2021 ...
Breaking Medicine Technology: